Ajanta Pharma receives US FDA approval of antifungal voriconazole tablet

Ajanta Pharma Limited has received final approval for voriconazole tablet (50 mg & 200 mg) from the US Food and Drug Administration (FDA). Voriconazole is a triazole antifungal for treatment of serious invasive fungal infections and the generic version of Vfend, manufactured by PF Prism CV.
 
Voriconazole tablets is part of ever-growing portfolio of products that Ajanta has developed for the US market. To date, the US FDA has granted Ajanta Pharma ten ANDA final approvals and two tentative approvals. An additional 14 ANDAs are under review with FDA.